The drug lowered the genetic instructions in the liver for making the bad cholesterol protein, but didn’t change the instructions for clearing it from the blood.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Randomized Controlled Trial

Animal

1997 Nov

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Score: 11

DOI: 10.1161/01.ATV.17.11.2589

Similar Assertions

The same cholesterol drug also made fewer bad cholesterol particles (LDL) in pigs by slowing down how much was made, not by clearing them faster.

89%

The drug lowered several types of bad fats in the pigs’ blood — including total cholesterol, LDL cholesterol, and triglycerides — by up to 31%.

89%

Giving pigs a cholesterol-lowering drug called atorvastatin for three weeks made their livers produce less of a key protein (apoB) that helps form bad cholesterol particles, without changing how fast those particles were cleared from the blood.

86%

The drug seemed to make less of the bad cholesterol particle by turning fewer big particles into smaller ones, but this effect wasn’t strong enough to be sure it wasn’t just chance.

80%

Atorvastatin doesn’t just lower bad cholesterol — it also lowers overall cholesterol and a key protein linked to heart disease, and higher doses make these effects stronger.

73%